Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays
- PMID: 1638531
Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays
Abstract
The affinity of a monoclonal antibody for its tumor-associated antigen is one of several parameters governing in vivo monoclonal antibody distribution. However, there is a lack of apparent correlation between the affinity of a bivalent monoclonal antibody measured using equilibrium binding experiments and its in vivo delivery. Furthermore, differences in the reported affinity for identical antibody/antigen pairs are quite common in the literature. In this paper, both of these discrepancies are addressed in terms of variation in avidity due to bivalent interaction. The enhancement of avidity afforded by bivalent attachment is addressed theoretically by extending the model of Crothers and Metzger (Immunochemistry, 9: 341-357, 1972). Theoretical assessment of Lineweaver-Burk, Scatchard, Steward-Petty, Langmuir, fluorescence recovery after photobleaching, and Sips models demonstrates quantitatively that the measured affinity using equilibrium binding experiments may vary over four orders of magnitude with similar variation in experimental cellular antigen density. Further, the measured affinity is a function of the experimental protocol. Predictions of avidity enhancement were confirmed experimentally using fluorescence recovery after photobleaching. These experiments measured the equilibrium binding constant and concentration of binding sites for an immunoglobulin G monoclonal antibody and its F(ab) fragment directed against the rabbit VX2 carcinoma cell line. Bivalent binding data agree quantitatively with those predicted by the bivalent model with no adjustable parameters. It is concluded that bivalent equilibrium binding constants are useful only in antibody screening, where experimental conditions are identical for all series. They must be used with caution in predicting in vivo antibody distribution, and it is recommended that the intrinsic, monovalent affinity be measured in tandem with any bivalent antibody study as a standard reference.
Similar articles
-
Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.Cancer Res. 2000 Nov 15;60(22):6434-40. Cancer Res. 2000. PMID: 11103810
-
Measurement of the functional affinity constant of a monoclonal antibody for cell surface receptors using kinetic exclusion fluorescence immunoassay.J Immunol Methods. 2005 Sep;304(1-2):1-14. doi: 10.1016/j.jim.2005.04.009. J Immunol Methods. 2005. PMID: 16098983
-
Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model.Cancer Res. 2000 Dec 15;60(24):7008-13. Cancer Res. 2000. PMID: 11156404
-
[Dynamics of antigen-antibody interaction--an introduction].Nihon Rinsho. 1995 Sep;53(9):2126-33. Nihon Rinsho. 1995. PMID: 7474369 Review. Japanese.
-
Affinity and avidity in antibody-based tumor targeting.Cancer Biother Radiopharm. 2009 Apr;24(2):155-61. doi: 10.1089/cbr.2009.0627. Cancer Biother Radiopharm. 2009. PMID: 19409036 Free PMC article. Review.
Cited by
-
A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.Blood. 2021 Oct 7;138(14):1258-1268. doi: 10.1182/blood.2020010331. Blood. 2021. PMID: 34077951 Free PMC article.
-
Molecular Interaction Characterization Strategies for the Development of New Biotherapeutic Antibody Modalities.Antibodies (Basel). 2020 Mar 25;9(2):7. doi: 10.3390/antib9020007. Antibodies (Basel). 2020. PMID: 32218192 Free PMC article.
-
An Asymptotic Analysis of Bivalent Monoclonal Antibody-Antigen Binding.Bull Math Biol. 2025 Aug 26;87(10):135. doi: 10.1007/s11538-025-01520-3. Bull Math Biol. 2025. PMID: 40858913 Free PMC article.
-
Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.Pharmaceutics. 2021 Mar 21;13(3):422. doi: 10.3390/pharmaceutics13030422. Pharmaceutics. 2021. PMID: 33800976 Free PMC article. Review.
-
Evolving story of autoantibodies in systemic lupus erythematosus.J Autoimmun. 2020 Jun;110:102356. doi: 10.1016/j.jaut.2019.102356. Epub 2019 Dec 4. J Autoimmun. 2020. PMID: 31810857 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources